What Is the REVS ETF? Returns, Fees, Holdings, and Alternative ETFs Explained
The Columbia Research Enhanced Value ETF (REVS) is a passive product that selects US value stocks through research analysis. Its annual dividend, research-enhanced structure, and differences in selection methods versus related products such as VLUE, JAVA, and FVAL are the key selection criteria.
What Is the Columbia Research Enhanced Value ETF?
This is a passive ETF that applies research-based analysis to select undervalued US value stocks. It places greater weight on value stocks with high research scores, aiming for better performance than a general value index.
It suits value-oriented investors who want exposure to US value stocks screened with research, and who are willing to accept relative weakness during growth-led market phases.
It is an ETF managed by Columbia using a passive (index-tracking) approach.
How Does the Columbia Research Enhanced Value ETF Invest?
| Item | Details |
|---|---|
| Investment target | US value stocks |
| Management style | Passive (research-enhanced index) |
| Selection criteria | Undervaluation + research score |
| Dividend frequency | Annual dividend |
| Total expense ratio | 0.19% |
The ETF tracks a rules-based index that overweights undervalued US value stocks that research analysis has rated highly. Unlike a simple value index, it adds a research score to screen out undervalued stocks that are more likely to underperform, while keeping costs low.
- Combines value stocks with a research score
- Low-cost, rules-based management
Columbia Research Enhanced Value ETF Size and Costs (AUM and Management Fee)
Assets under management (AUM) stand at $414.3M, and the total expense ratio is 0.19% per year.
The main point of comparison is its rules-based selection with an added research score, versus simple value ETFs or actively managed value ETFs.
Columbia Research Enhanced Value ETF Performance and Trends
US value stocks are driven by interest rates, the economic cycle, and style rotation. Value strategies tend to be strong when value stocks are in favor and weak when growth stocks lead. Because a research score is added, performance can differ somewhat from that of a general value index.
Fund flows into value stocks diverge depending on style rotation, risk appetite, and demand for value investing, and money sometimes moves into related products when interest in value investing rises. It is also worth watching how performance shifts with interest rates and style rotation.
Columbia Research Enhanced Value ETF Pros and Cons
Research enhancement and low costs are its strengths, while weakness in growth-led phases, tracking differences, and market risk are considerations.
💪 Key Strengths
⚠️ Points to Watch
Columbia Research Enhanced Value ETF Alternatives and Related Products
For value factor exposure, direct substitutes include VLUE, and for those who want active value management, products such as JAVA are also worth comparing. Investors seeking another form of value factor exposure can also consider products such as FVAL. The three products shown in the table, VLUE, JAVA, and FVAL, differ in selection method across value factor and active value strategies, and this ETF is differentiated by combining value stocks with a research score.
| Ticker | Name | Price | Change | AUM | Total Expense Ratio | Dividend Yield | 1Y |
|---|---|---|---|---|---|---|---|
| Avantis U.S. Small Cap Value ETF | $114.40 | -1.8% | $31.0B | 0.25% | 1.33% | +21.8% | |
| iShares MSCI USA Value Factor ETF | $170.59 | -4.0% | $8.6B | 0.15% | 1.81% | +36.8% | |
| JPMorgan Active Value ETF | $79.37 | -1.9% | $7.2B | 0.44% | 1.19% | +17.0% | |
| Nuveen ESG Large-Cap Value ETF | $51.28 | -2.2% | $2.5B | 0.26% | 1.44% | +17.6% | |
| Fidelity Value Factor ETF | $75.01 | -3.0% | $1.3B | 0.15% | 1.64% | +10.3% |
| Ticker | Name | Weight | Price | Change | Market Cap | P/E | Dividend Yield |
|---|---|---|---|---|---|---|---|
| AAPL | Apple Inc | 0.08% | $342.56 | -1.9% | $4.98T | 38.2 | 0.33% |
| MSFT | Microsoft Corp | 0.07% | $484.52 | -2.8% | $3.60T | 25.3 | 0.81% |
| BAC | Bank Of America Corp | 0.04% | $47.04 | -3.1% | $324.6B | 11.2 | 2.55% |
| XOM | ExxonMobil Holdings Corp | 0.03% | $159.99 | +0.7% | $652.6B | 16.4 | 2.6% |
| PG | Procter & Gamble Co | 0.03% | $169.37 | +0.9% | $392.6B | 25.5 | 2.59% |
| WFC | Wells Fargo & Co | 0.03% | $78.62 | -2.5% | $236.0B | 11.1 | 2.42% |
| GOOGL | Alphabet Inc | 0.03% | $265.29 | -2.7% | $3.23T | 13.8 | 0.33% |
| CSCO | Cisco Systems Inc | 0.03% | $90.64 | -4.3% | $357.3B | 24.1 | 1.87% |
| CVX | Chevron Corp | 0.03% | $208.37 | +0.9% | $409.5B | 15.3 | 3.42% |
| GOOG | Alphabet Inc | 0.03% | $264.00 | -2.6% | $3.24T | 13.8 | 0.33% |
Columbia Research Enhanced Value ETF Investor Checkpoints
Here are the points to review before investing in REVS. Research enhancement and low costs are attractive, but relative weakness in growth-led phases, tracking differences, and market risk should be checked in advance. It is also a good idea to compare it with simple value and active value products.
| Checkpoint | What to check | Current status |
|---|---|---|
| 🔬 Research enhancement | Review research score selection | Research reflected |
| 📊 Value orientation | Review undervalued stock exposure | Value reflected |
| 🔄 Style rotation | Review value and growth phases | Needs checking |
| 💵 Expense ratio | Check fees for rules-based management | On the low side |
Relative weakness in growth-led phases and tracking differences from research score selection are the main variables for long-term performance, and the selection process can make its composition differ from a general value index. Even with a focus on value stocks, losses can occur during market crashes.
It is a suitable candidate for value-oriented investors who want to invest in US value stocks screened with research. If you want a value factor or active value exposure, it is advisable to compare products such as VLUE and JAVA, and if you want research-enhanced value exposure, to consider this product alongside them.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
This article reflects information as of June 10, 2026.